Heart failure patients treated with finerenone (Kerendia; Bayer AG) are more likely to have an early decline in kidney function than those treated with placebo, but the decline should not be construed ...

Over a median of 32 months, finerenone significantly reduced the primary endpoint, with 1,083 events in the finerenone group and 1,283 events in the placebo group (rate ratio 0.84; 95% confidence ...